Nonetheless, due to the limitation of generalizability specially for countries with developing economies or different healthcare systems than Qatar, similar evaluations should be carried out in different settings to assure a holistic guidance for the most cost-effective use of CDK4/6 inhibitors in HR+/HER2- advanced breast cancer. This evidence concerns the gene CDK4 and breast carcinoma.